Disc Medicine, Inc. (NASDAQ:IRON) Given Average Rating of “Moderate Buy” by Brokerages

Disc Medicine, Inc. (NASDAQ:IRON) has been assigned an average rating of “Moderate Buy” from the thirteen analysts that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have issued a buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $119.4545.

A number of equities research analysts have recently commented on IRON shares. Raymond James Financial restated a “market perform” rating on shares of Disc Medicine in a research report on Thursday, January 15th. Wells Fargo & Company raised their price objective on Disc Medicine from $91.00 to $109.00 and gave the company an “overweight” rating in a report on Tuesday, December 16th. Cantor Fitzgerald boosted their price objective on Disc Medicine from $132.00 to $153.00 and gave the company an “overweight” rating in a research report on Friday, October 17th. Wedbush reaffirmed an “outperform” rating on shares of Disc Medicine in a research note on Thursday, January 15th. Finally, TD Cowen reiterated a “buy” rating on shares of Disc Medicine in a research report on Friday, December 19th.

Insider Buying and Selling at Disc Medicine

In other news, Director Kevin Bitterman sold 68,923 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $91.24, for a total value of $6,288,534.52. Following the transaction, the director owned 14,161 shares in the company, valued at $1,292,049.64. This trade represents a 82.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO John D. Quisel sold 40,000 shares of Disc Medicine stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $93.05, for a total value of $3,722,000.00. Following the completion of the sale, the chief executive officer directly owned 171,828 shares in the company, valued at $15,988,595.40. This represents a 18.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 275,470 shares of company stock valued at $24,966,170. Insiders own 3.64% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. ANTIPODES PARTNERS Ltd acquired a new stake in Disc Medicine during the 4th quarter worth $33,000. Aster Capital Management DIFC Ltd purchased a new position in shares of Disc Medicine in the third quarter worth about $38,000. CWM LLC boosted its position in Disc Medicine by 213.5% during the second quarter. CWM LLC now owns 1,044 shares of the company’s stock worth $55,000 after acquiring an additional 711 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Disc Medicine by 15.6% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,338 shares of the company’s stock worth $71,000 after acquiring an additional 181 shares during the last quarter. Finally, KBC Group NV purchased a new stake in Disc Medicine during the 4th quarter valued at about $80,000. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Disc Medicine Trading Up 1.8%

Shares of NASDAQ:IRON opened at $79.72 on Friday. The company has a current ratio of 23.45, a quick ratio of 23.45 and a debt-to-equity ratio of 0.05. Disc Medicine has a 12-month low of $30.82 and a 12-month high of $99.50. The business has a 50 day moving average of $81.92 and a two-hundred day moving average of $74.83. The company has a market capitalization of $3.01 billion, a PE ratio of -14.90 and a beta of 0.88.

Disc Medicine (NASDAQ:IRON) last posted its earnings results on Thursday, November 6th. The company reported ($1.77) earnings per share for the quarter, missing the consensus estimate of ($1.48) by ($0.29). As a group, analysts forecast that Disc Medicine will post -4.07 EPS for the current year.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.